Thailand says AstraZeneca asked to delay delivery of 61 mln vaccine doses



(Updates with Taiwanese comment, detail on Thai production)

By Panarat Thepgumpanat and Panu Wongcha-um

BANGKOK, July 15 (Reuters) - AstraZeneca AZN.L has asked Thailand to extend the timeline for the delivery of 61 million doses of its COVID-19 vaccine by five months, a deputy minister said on Thursday, a move likely to further disrupt the country's sluggish vaccine rollout.

The reported request points to a slow production ramp-up at its local manufacturing partner, which had initial production and delivery issues, even as AstraZeneca reassured it would be back on track from this month to meet its supply commitments to Thailand and other Southeast Asian nations.

The comments come a day after Thailand said it was considering curbing exports of the locally produced AstraZeneca vaccines to fight its own crisis, sparking concerns of vaccine protectionism.

The Thailand dispute marks a fresh setback for the drugmaker which had other production glitches earlier and is in a legal battle with the European Union over shipment delays, while its vaccine has been linked to rare cases of blood clotting.

Deputy Health Minister Sathit Pitutacha told MCOT television station that AstraZeneca had requested to delay the delivery of all 61 million doses it pledged to Thailand from its Thai production facility from December this year to May 2022.

AstraZeneca did not immediately respond to a request for comment on Sathit's statement.

Sathit also said the drugmaker had the capacity to produce 15 million doses of vaccine per month at the Siam Bioscience production facility it is contracted with in Thailand and that capacity could expand in the future.

AstraZeneca was now promising to deliver 40% of what is produced at that facility to Thailand, Sathit said, adding that Thailand will ask the company for more doses.

"We must negotiate with them, because in this situation we need more vaccine," Sathit said.

"We want 10 million doses because the original plan was 10 million doses," he said referring to the previous monthly delivery target.

Thailand is suffering its worst COVID-19 outbreak yet and reported a record 98 coronavirus deaths on Thursday, taking total fatalities to 3,032 since the pandemic began last year.

It also reported 9,186 new infections, bringing total cases to 372,215.

Thailand's main vaccine rollout started last month and only about 5% of its more than 66 million people have been fully vaccinated.

POSSIBLE EXPORT CURBS

Sathit's comments on monthly production of 15 million doses are among the first clear statements of the production by Siam Bioscience, which has been shrouded in a veil of secrecy.

The company is 100% owned by King Maha Vajiralongkorn, and Thai officials have long dodged questions as to whether it was falling short of production goals. Thailand has strict laws against insulting the monarchy that punish offenders with up to 15 years in prison.

Responding to a request for comment on possible export curbs, AstraZeneca said late on Wednesday its Thai-manufactured vaccine "is of critical importance" to neighbouring countries where the pandemic is also accelerating.

"We are actively working with the government in Thailand and governments across Southeast Asia to continue to deliver equitable vaccine access to the region," it said.

AstraZeneca does not make its distribution deals public, but its website says its Thai production would supply several countries in Southeast Asia including Malaysia, the Philippines and Indonesia. Taiwan also has a deal to purchase Thai-manufactured AstraZeneca vaccines.

"We are continuing to closely observe and pay attention to this. We are also maintaining close touch with AstraZeneca," Taiwanese Deputy Health Minister Hsueh Jui-yuan told reporters.

He said that apart from 117,000 AstraZeneca vaccines that arrived from South Korea earlier this year, the rest of their direct order from the company for 10 million doses is from Thailand.

A representative of Indonesia's health ministry said "there doesn't seem to be an impact" in the shipment of AstraZeneca in light of possible Thailand export curbs.
Additional reporting by Ben Blanchard in Taipei and Stanley Widianto in Jakarta; Editing by Ed Davies and Ana Nicolaci da Costa

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Gumagamit kami ng cookies para mabigyan ka ng mahusay na karanasan sa aming website. Magbasa pa o palitan ang iyong cookie settings.

Babala sa Risk: Ang iyong kapital ay maaaring malugi. Ang mga produktong naka-leverage ay maaaring hindi para sa lahat. Tingnan ang aming Risk Disclosure.